Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200 Day Moving Average – What’s Next?

Tenax Therapeutics, Inc. (NASDAQ:TENX)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.54 and traded as high as $6.68. Tenax Therapeutics shares last traded at $6.52, with a volume of 14,478 shares.

Analyst Ratings Changes

Several equities research analysts have commented on TENX shares. StockNews.com started coverage on shares of Tenax Therapeutics in a research report on Thursday, September 26th. They set a “sell” rating on the stock. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. William Blair started coverage on shares of Tenax Therapeutics in a report on Monday, September 30th. They issued an “outperform” rating on the stock. Guggenheim started coverage on shares of Tenax Therapeutics in a report on Monday, October 14th. They issued a “buy” rating and a $16.00 target price on the stock. Finally, Leerink Partners started coverage on shares of Tenax Therapeutics in a report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 target price on the stock. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Tenax Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Tenax Therapeutics Trading Up 0.3 %

The stock’s fifty day moving average price is $5.86 and its two-hundred day moving average price is $4.54.

Institutional Trading of Tenax Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Sphera Funds Management LTD. bought a new position in Tenax Therapeutics in the 3rd quarter valued at approximately $101,000. Vestal Point Capital LP bought a new position in Tenax Therapeutics in the 3rd quarter valued at approximately $288,000. Finally, Stonepine Capital Management LLC bought a new position in Tenax Therapeutics in the 3rd quarter valued at approximately $173,000. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.